ArticleMolecular & cellular proteomics : MCP2026
Modanovo: A Unified Model for Post-translational Modification-Aware De Novo Sequencing Using Experimental Spectra From In Vivo and Synthetic Peptides.
Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- usiGrabber: automating the curation of proteomics spectra data at scale, making large datasets ready for use in machine learning systems.Bioinformatics (Oxford, England) · 2026Article
- Modanovo: A Unified Model for Post-translational Modification-Aware De Novo Sequencing Using Experimental Spectra From In Vivo and Synthetic Peptides.Molecular & cellular proteomics : MCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-translational modifications (PTMs) play a central role in cellular regulation and are implicated in numerous diseases. Database searching remains the standard for identifying modified peptides from tandem mass spectra but is hindered by the combinatorial expansion of modification types and sites. De novo peptide sequencing offers an attractive alternative, yet existing methods remain limited to unmodified peptides or a narrow set of PTMs. Here, we curated a large dataset of spectra from endogenous and synthetic peptides from ProteomeTools spanning 19 biologically relevant amino acid-PTM combinations, covering phosphorylation, acetylation, and ubiquitination. We used this dataset to develop Modanovo, an extension of the Casanovo transformer architecture for de novo peptide sequencing. Modanovo achieved robust performance across these amino acid-PTM combinations (median area under the precision-coverage curve 0.92), while maintaining performance on unmodified peptides (0.93), nearly identical to Casanovo (0.94). The model outperformed π-PrimeNovo-PTM and InstaNovo-P and showed increased precision and complementarity to the database search tool MSFragger. Robustness was confirmed across independent datasets, particularly at peptide lengths frequently represented in the curated dataset. Applied to a phosphoproteomics dataset from monkeypox virus-infected cells, Modanovo recovered numerous confident peptides not reported by database search, including new viral phosphosites supported by spectral evidence, thereby demonstrating its complementarity to database-driven identification approaches. These results establish Modanovo as a broadly applicable model for comprehensive de novo sequencing of both modified and unmodified peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.